成都瑞沐生物医药科技

Ruimu Biotech is a clinical-stage biopharmaceutical company based in Chengdu, China, specializing in the discovery and development of innovative small molecule therapeutics. The company leverages its structure-based drug design (SBDD) and fragment-based drug design (FBDD) platforms to target high-value pathways in immunology, oncology, and metabolic diseases. Its lead candidate, RM-001, is a highly selective TYK2 inhibitor currently undergoing clinical evaluation for autoimmune conditions such as psoriasis. Ruimu Biotech aims to address significant unmet medical needs through precision medicine and efficient drug optimization within the Chengdu Tianfu International Bio-Town ecosystem.